A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif (Registered)) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Trial Profile

A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif (Registered)) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Jul 2015 Planned End Date changed from 1 Oct 2020 to 1 Jul 2021 as reported by ClinicalTrials.gov.
    • 22 Jul 2015 Planned primary completion date changed from 1 Oct 2020 to 1 Jul 2021 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top